rilmenidine teva 1 mg tabletes
teva pharma b.v., netherlands - rilmenidīns - tablete - 1 mg
taruza 1 mg tabletes
zentiva, k.s., czech republic - rilmenidīns - tablete - 1 mg
rilmenidine grindeks 1 mg tabletes
grindeks, as, latvia - rilmenidīns - tablete - 1 mg
swispara 500 mg/12,2 mg pulveris iekšķīgi lietojama šķīduma pagatavošanai
sandoz d.d., slovenia - paracetamolum, phenylephrini hydrochloridum - pulveris iekšķīgi lietojama šķīduma pagatavošanai - 500 mg/12,2 mg
swispara 1000 mg/12,2 mg pulveris iekšķīgi lietojama šķīduma pagatavošanai
sandoz d.d., slovenia - paracetamolum, phenylephrini hydrochloridum - pulveris iekšķīgi lietojama šķīduma pagatavošanai - 1000 mg/12,2 mg
tegretol cr 200 mg ilgstošās darbības apvalkotās tabletes
novartis baltics, sia, latvia - karbamazepīns - modificētās darbības apvalkotā tablete - 200 mg
finlepsin 200 mg tabletes
teva pharma b.v., netherlands - karbamazepīns - tablete - 200 mg
tegretol cr 400 mg ilgstošās darbības apvalkotās tabletes
novartis baltics, sia, latvia - karbamazepīns - modificētās darbības apvalkotā tablete - 400 mg
xtandi
astellas pharma europe b.v. - enzalutamide - prostatas audzēji - endokrīnā terapija - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
apel 600 mg apvalkotās tabletes
medochemie ltd., cyprus - linezolīds - apvalkotā tablete - 600 mg